Keros Therapeutics reports Q3 results
| KROS Stock | USD 10.32 0.17 1.67% |
Slightly above 55% of Keros Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Keros Therapeutics suggests that many traders are impartial. Keros Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Keros Therapeutics' earnings reports, geopolitical events, and overall market trends.
Keros |
Keros Therapeutics reports Q3 financial results with GAAP EPS of -1.41 and revenue of 0.39M, showing strong cash position growth.
Read at seekingalpha.com
 |
Keros Therapeutics Fundamental Analysis
We analyze Keros Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Keros Therapeutics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Keros Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Keros Therapeutics stock to make a market-neutral strategy. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics with similar companies.
Peers
Keros Therapeutics Related Equities
| ANAB | AnaptysBio | 10.01 | ||||
| SRZN | Surrozen | 9.44 | ||||
| IPSC | Century Therapeutics | 2.67 | ||||
| LRMR | Larimar Therapeutics | 2.14 | ||||
| BOLT | Bolt Biotherapeutics | 2.04 | ||||
| MGTX | MeiraGTx Holdings | 1.52 | ||||
| IDYA | Ideaya Biosciences | 1.16 | ||||
| GLUE | Monte Rosa | 0.89 | ||||
| MLYS | Mineralys Therapeutics, | 0.39 | ||||
| KZR | Kezar Life | 0.34 | ||||
| HRMY | Harmony Biosciences | 0.26 | ||||
| AVTE | Aerovate Therapeutics | 0.41 | ||||
| FENC | Fennec Pharmaceuticals | 0.89 | ||||
| SNDX | Syndax Pharmaceuticals | 1.06 | ||||
| REPL | Replimune | 1.33 | ||||
| JANX | Janux Therapeutics | 2.15 | ||||
| EWTX | Edgewise Therapeutics | 2.42 | ||||
| ERAS | Erasca | 3.68 |
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.